REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients
Titel:
REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients
Auteur:
Shitara, K. Yamanaka, T. Denda, T. Tsuji, Y. Shinozaki, K. Komatsu, Y. Kobayashi, Y. Furuse, J. Okuda, H. Asayama, M. Akiyoshi, K. Kagawa, Y. Kato, T. Oki, E. Ando, T. Hagiwara, Y. Ohashi, Y. Yoshino, T.